Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07398417 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

Study acronym: FORWARD
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 51 to 53v3
  2. Trial sites expanded: 16 → 51 locationsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.
Trial Details
NCT Number NCT07398417
Lead Sponsor Axsome Therapeutics, Inc.
Conditions Fibromyalgia
Enrollment 620 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov